Zahra Zandi et al. [30] also reported that blocking TLR-4 with TAK-242 (also known as restorvid, which can specifically bind to the TIR domain of TLR-4) could down-regulate the expression of EGFR, c—Myc, and other genes and specifically inhibit the activity of TLR-4+ BC cells, ultimately achieving the goal of improving chemotherapy sensitivity [31]. Here, TLR4 is linked to breast cancer.